Dr. Deepak L. Bhatt
@DLBHATTMD
Followers
40K
Following
47K
Media
204
Statuses
16K
Dr. Deepak L. Bhatt is Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine. Bio and COI: https://t.co/ngtk4hxfDG.
New York City
Joined December 2009
After 14 wonderful years at @BrighamWomens, @MassGenBrigham, @DanaFarber, and @VABostonHC, I am happy to announce that I will be the Director of @MountSinaiHeart at @MountSinaiNYC and the Dr. Valentin Fuster Professor of CV Medicine at @IcahnMountSinai.
mountsinai.org
271
91
2K
Tune in LIVE to listen to Dr. Deepak Bhatt discuss the “Top 10 Trials at The Mount Sinai Fuster Heart Hospital” https://t.co/DbgOansv33
#cardiox #cardiotwitter #cardiology #topten2025
0
6
22
Tune in LIVE to listen to Dr. Deepak Bhatt discuss the “Top 10 Trials at The Mount Sinai Fuster Heart Hospital” https://t.co/DbgOansv33
#cardiox #cardiotwitter #cardiology #topten2025
0
6
22
South Asians and Cardiovascular Risk. @DLBHATTMD #SouthAsianCVD #SouthAsianHeart #CardioEpi #GlobalCardio #HealthEquity #CardioResearch #CVDrisk #PrecisionMedicine #EthnicHealthDisparities #PreventiveCardiology @DrMarthaGulati @ErinMichos @drjohnm @SVRaoMD @DBelardoMD
0
3
9
Adipokine hypothesis of HFpEF. https://t.co/oDeKJi4IOp
@DLBHATTMD @mvaduganathan @ShelleyZieroth @JavedButler1 @BobbyYanagawa @GilbertTangMD @cscs_sccc @UofTSurgery
3
6
49
South Asians and Cardiovascular Risk. @DLBHATTMD #SouthAsianCVD #SouthAsianHeart #CardioEpi #GlobalCardio #HealthEquity #CardioResearch #CVDrisk #PrecisionMedicine #EthnicHealthDisparities #PreventiveCardiology @DrMarthaGulati @ErinMichos @drjohnm @SVRaoMD @DBelardoMD
0
3
9
Great night at the @MountSinaiNYC Board of Trustees Dinner with my former boss, Dr. Toby Cosgrove, prior CEO of @ClevelandClinic, and current boss @Dr_BrendanCarr, CEO of @MountSinaiNYC! @CleClinicNews @IcahnMountSinai
1
4
54
Perspectives on Artificial Intelligence in Medical... : Journal of Cardiovascular Pharmacology https://t.co/embivanu3u
#AI #cardiology #cardiovascular
journals.lww.com
of editors of medical journals on AI. A structured online questionnaire was developed and distributed to editors-in-chief of medical journals worldwide. The survey comprised 27 concise questions...
1
5
14
⭐ What this means: --Traditional screening tools miss many at-risk people --Even when risks are recognized, preventive therapies often aren't started --We need a better strategy to identify disease earlier @DLBHATTMD #cardiotwitter #CAD #CCTA @SCCT
https://t.co/uqzVbK3ioj
0
4
7
Adipokine hypothesis of HFpEF. https://t.co/oDeKJi4IOp
@DLBHATTMD @mvaduganathan @ShelleyZieroth @JavedButler1 @BobbyYanagawa @GilbertTangMD @cscs_sccc @UofTSurgery
3
6
49
Great night at the @MountSinaiNYC Board of Trustees Dinner with my former boss, Dr. Toby Cosgrove, prior CEO of @ClevelandClinic, and current boss @Dr_BrendanCarr, CEO of @MountSinaiNYC! @CleClinicNews @IcahnMountSinai
1
4
54
Serum Apolipoprotein Panel improves cardiovascular risk prediction and identifies patients who benefit from PCSK9 inhibitors, enabling personalized care in post-ACS. @VeraBittner2 @gabrielsteg @DLBhattMD
@W66588221White @HeartBobH @Christa
https://t.co/oqrKXjNlcL
1
4
16
🚨Missed Opportunities Before a Heart Attack 📊 4.6M US patients • 50% had no documented symptoms • 18% had no traditional risk factors (SMuRFs) • 22% had no physician visits • 63% were not on preventive therapy Younger adults & men least likely to be recognised or
0
4
15
There is a benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT https://t.co/W6196RpWDz
0
4
17
🚨Missed Opportunities Before a Heart Attack 📊 4.6M US patients • 50% had no documented symptoms • 18% had no traditional risk factors (SMuRFs) • 22% had no physician visits • 63% were not on preventive therapy Younger adults & men least likely to be recognised or
0
4
15
There is a benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT https://t.co/W6196RpWDz
0
4
17
Serum Apolipoprotein Panel improves cardiovascular risk prediction and identifies patients who benefit from PCSK9 inhibitors, enabling personalized care in post-ACS. @VeraBittner2 @gabrielsteg @DLBhattMD
@W66588221White @HeartBobH @Christa
https://t.co/oqrKXjNlcL
1
4
16
⭐ What this means: --Traditional screening tools miss many at-risk people --Even when risks are recognized, preventive therapies often aren't started --We need a better strategy to identify disease earlier @DLBHATTMD #cardiotwitter #CAD #CCTA @SCCT
https://t.co/uqzVbK3ioj
0
4
7
Icosapent ethyl reduces MI across MI subtypes and sizes of MI in statin-treated patients with elevated TGs at increased CV risk @rgiugliano
https://t.co/MLpbEW4Jls
0
3
17
Perspectives on Artificial Intelligence in Medical... : Journal of Cardiovascular Pharmacology https://t.co/embivanu3u
#AI #cardiology #cardiovascular
journals.lww.com
of editors of medical journals on AI. A structured online questionnaire was developed and distributed to editors-in-chief of medical journals worldwide. The survey comprised 27 concise questions...
1
5
14
Icosapent ethyl reduces MI across MI subtypes and sizes of MI in statin-treated patients with elevated TGs at increased CV risk @rgiugliano
https://t.co/MLpbEW4Jls
0
3
17